Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: John Wright who wrote (236)	1/28/1998 11:17:00 PM
From: Dr. John M. de Castro	Respond to of 1494

These results should be sufficient to get money and partners. They are not spectacular by any means. But, with the very small group sizes like in this study, there is insufficient statistical power to obtain significance. That is typical of a phase II trial. A phase III is powered sufficiently to demonstrate significance. The important thing here is the effect sizes. 30%, 29% and 18% above placebo is just outstanding. This is a very difficult group to treat, Nothing really works for them. So, this kind of effect size is excellent. Although much of the results were not statistically significant, the effect sizes are clinically significant. In the long run that means that patients will take it and Doctors will prescribe it. Picture 800,000 patients in pain with nothing available to take. They are going to want memantine. This is a gigantic market and remember that memantine has to be taken chronically. So they will be buying it over and over again. This could be a tremendous cash cow. I can imagine that this has to be a very attractive circumstance for potential marketing partners. If you can't tell, I'm excited. :-) John de C